WO2023214356 - A MICRONUTRIENT MIXTURE AND METHOD OF TREATING ESTROGEN RELATED COMPLICATIONS USING THE MICRONUTRIENT MIXTURE
National phase entry:
Publication Number
WO/2023/214356
Publication Date
09.11.2023
International Application No.
PCT/IB2023/054666
International Filing Date
04.05.2023
Title **
[English]
A MICRONUTRIENT MIXTURE AND METHOD OF TREATING ESTROGEN RELATED COMPLICATIONS USING THE MICRONUTRIENT MIXTURE
[French]
MÉLANGE DE MICRONUTRIMENTS ET PROCÉDÉ DE TRAITEMENT DE COMPLICATIONS LIÉES AUX ŒSTROGÈNES À L'AIDE DU MÉLANGE DE MICRONUTRIMENTS
Applicants **
RATH, Matthias W
Inventors
NIEDZWIECKI, Aleksandra
LOPEZ, Gabriela
BOULIKAS, Parthena
GOC, Anna
Priority Data
63/338,043
04.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2176 | |
| EPO | Filing, Examination, Granting | 7154 | |
| Japan | Filing, Examination, Granting | 2192 | |
| South Korea | Filing, Examination, Granting | 2087 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
18,949
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A Basic mix or Mix 1 or Mix 2 is highly effective in treating estrogen related complications in females. The estrogen related diseases such as cancer are also treated if they are Apo E based manifestations. The basic mix or Mix 1 or Mix 2 comprises of a combination of Vitamin C in ascorbate form 10 mg-100,000 mg, Vitamin E in D-alpha-tocopherol form 1 mg-3,000 mg, Vitamin B5 1 mg-20,000 mg, Vitamin B6 1 mg-1, 000 mg, Folic acid 1 mcg-3,000 mcg, Iodine (Kelp) 1 mcg-2,000 mcg, Selenium 1 mcg-2,000 mcg, Choline 1 mg-5,000 mg, Inositol 1 mg-5000 mg, Phosphatidyl serine 1 mg-1,500 mg, Daidzein 1 mg-1,500 mg, Glycitein 0.1 mg-1,000 mg, Genistein 1 mg-2,500 mg, Red clover 1 mg-1,500 mg, Rosemary extract 1 mg- 6,000 mg, Chaste tree berry 1 mg- 2,000 mg. The treatment by administering Mix 1 decreases estrogen dependent breast cancer cells proliferation and decrease in expression of cancer promoting cellular markers in cancer cells (iNOS, ApoE).[French]
Selon l'invention, un mélange de base ou un mélange 1 ou un mélange 2 est très efficace dans le traitement de complications liées aux œstrogènes chez les femmes. Les maladies liées aux œstrogènes telles que le cancer sont également traitées s'il s'agit de manifestations basées sur des apolipoprotéines E. Le mélange de base ou le mélange 1 ou le mélange 2 est constitué d'une combinaison de vitamine C sous forme d'ascorbate 10 mg-100000 mg, de vitamine E sous forme de D-alpha-tocophérol 1 mg-3000 mg, de vitamine B5 1 mg-20000 mg, de vitamine B6 1 mg-1, 000 mg, d'acide folique 1 mcg-3000 mcg, d'iode (Kelp) 1 mcg-2000 mcg, de sélénium 1 mcg-2000 mcg, de choline 1 mg-5000 mg, d'inositol 1 mg-5000 mg, de phosphatidylsérine 1 mg-1500 mg, de daidzéine 1 mg-1,500 mg, de glycéitine 0,1 mg-1000 mg, de génistéine 1 mg-2,500 mg, de trèfle violet 1 mg-1,500 mg, d'extrait de romarin 1 mg- 6000 mg, de baie de gattilier 1 mg- 2000 mg. Le traitement par administration du mélange 1 diminue la prolifération des cellules du cancer du sein dépendant des œstrogènes et diminue l'expression des marqueurs cellulaires favorisant le cancer dans les cellules cancéreuses (iNOS, ApoE).